<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefazolin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefazolin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefazolin: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9214" href="/d/html/9214.html" rel="external">see "Cefazolin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11314" href="/d/html/11314.html" rel="external">see "Cefazolin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1045881"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (First Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462395"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-24492261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-24492261'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Preterm and term neonates: </i>IM, IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Body Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Postnatal Age</p></th>
<th align="center">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">≤2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/<b>day</b> divided every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg/kg/<b>day</b> divided every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">100 to 150 mg/kg/<b>day</b> divided every 6 to 8 hours</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg/kg/<b>day</b> divided every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg/kg/<b>day</b> divided every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">100 to 150 mg/kg/<b>day</b> divided every 6 to 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gestational age-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IM, IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Gestational Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">&lt;32 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">&lt;7 days</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">≥32 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours</p></td></tr></tbody></table>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perioperative: </i>Preterm and term neonates: IV: 30 mg/kg as a single dose; administer within 30 to 60 minutes prior to surgical incision; consider redosing in 4 hours if procedure lasts &gt;4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35203881','lexi-content-ref-23327981','lexi-content-ref-25038006','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35203881','lexi-content-ref-23327981','lexi-content-ref-25038006','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postoperative, cardiac surgery: </i>
<b>Note:</b> Continue for up to 48 hours after surgery; refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25038006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25038006'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≤7 days: IV: 30 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;7 days: IV: 30 mg/kg/dose every 8 hours.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F147112"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>): Infants, Children, and Adolescents: IM, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate infections: 25 to 100 mg/kg/day divided every 8 hours; maximum daily dose: 6 <b>g/day </b></p>
<p style="text-indent:-2em;margin-left:4em;">Severe infections (eg, bone/joint infections): 100 to 150 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 <b>g/day </b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Alternative agent for use in patients who are unable to take oral medication and who have penicillin or ampicillin allergy (excluding those with a history of anaphylaxis, angioedema, or urticaria) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>). Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: 50 mg/kg as a single dose administered 30 to 60 minutes prior to dental procedure; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment: </b> Children and Adolescents: IV: 100 mg/kg/day in divided doses every 8 hours; usual adult dose: 2,000 mg/dose; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 weeks; longer durations may be necessary; may use with or without gentamicin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>): Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis:</p>
<p style="text-indent:-2em;margin-left:6em;">Touch contamination of PD line: Intraperitoneal: 125 mg per liter</p>
<p style="text-indent:-2em;margin-left:6em;">Invasive dental procedures: IV: 25 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 1,000 mg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal or genitourinary procedures: IV: 25 mg/kg administered 60 minutes before procedure; maximum dose: 2,000 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: Intraperitoneal:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent: 20 mg/kg every 24 hours in the long dwell</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance: 125 mg per liter of dialysate</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="124cbd4a-6ad3-40b8-91ca-ae65ebae0a7d">Pneumonia, community-acquired pneumonia, <i>S. aureus</i>, methicillin susceptible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired pneumonia (CAP), </b>
<i>
<b>S. aureus</b></i>
<b>, methicillin susceptible:</b> Infants &gt;3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>); usual maximum dose for severe infections: 12 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0ca5bd9-1623-460f-81e8-47032f574ced">Skin and soft tissue infection, <i>S. aureus</i>, methicillin susceptible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, <i>S. aureus</i>, methicillin susceptible (mild to moderate):</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus</i>, methicillin susceptible skin and soft tissue infections including pyomyositis: IV: 50 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; higher doses may be required in severe cases; duration of therapy at least 5 days, but longer may be necessary in some cases, eg, febrile and neutropenic patients: 7 to 14 days; pyomyositis: 14 to 21 days</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus</i>, methicillin susceptible necrotizing infection of skin, fascia, or muscle: IV: 100 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; continue therapy until surgical debridement no longer necessary, clinical improvement and afebrile for 48 to 72 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Streptococcal, nonpurulent skin infection (cellulitis): IV: 100 mg/kg/day divided every 8 hours; maximum dose: 1,000 mg/dose; duration of therapy at least 5 days, but longer may be necessary in some cases</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Infants, Children, and Adolescents: IV: 30 mg/kg within 60 minutes prior to procedure, may repeat in 4 hours for prolonged procedure or excessive blood loss (eg, &gt;1,500 mL in adults); maximum dose dependent upon patient weight: Weight &lt;120 kg: 2,000 mg/dose; weight ≥120 kg: 3,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-AAP.1'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083952"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, and expert opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-29441476','lexi-content-ref-19397464','lexi-content-ref-7351609','lexi-content-ref-1936061','lexi-content-ref-32360445','lexi-content-ref-16163635','lexi-content-ref-20000886','lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-29441476','lexi-content-ref-19397464','lexi-content-ref-7351609','lexi-content-ref-1936061','lexi-content-ref-32360445','lexi-content-ref-16163635','lexi-content-ref-20000886','lexi-content-ref-14969569'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">The following dose adjustments assume a usual recommended dose of 25 to 50 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to &lt;50 mL/minute/1.73 m<sup>2</sup>: 25 to 30 mg/kg/dose every 12 hours; doses up to 50 mg/kg/dose may be needed for severe infections; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 30 mL/minute/1.73 m<sup>2</sup>: 25 to 30 mg/kg/dose every 24 hours; doses up to 50 mg/kg/dose may be needed for severe infections; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≤10 mL/minute/1.73 m<sup>2</sup>: 25 to 30 mg/kg/dose every 48 hours; doses up to 50 mg/kg/dose may be needed for severe infections; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Dialyzable: 35% to 65%.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Appropriate dosing requires consideration of drug penetration to site of infection, minimum inhibitory concentration (MIC) of bacteria, severity of illness, residual kidney function, and interval between dialysis sessions.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent dosing</i> (eg, 3 times weekly): IV: 25 to 50 mg/kg/dose after dialysis; maximum dose: 2,000 mg/dose. <b>Note:</b> Children with residual kidney function may require higher or more frequent dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, Adolescents: IV, IM: 25 to 30 mg/kg/dose every 24 to 48 hours; maximum dose: 1,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of ≥1,500 mL/m<sup>2</sup>/hour) unless otherwise noted; flow rates vary widely in pediatric patients. Appropriate dosing requires consideration of drug penetration to site of infection, MIC of bacteria, and severity of illness. Close monitoring of response and adverse reactions due to drug accumulation (eg, neurotoxicity) is important. Due to minimal data in pediatric patients receiving CRRT, consider monitoring serum concentrations (eg, trough concentration) if available. Dosing based on limited adult information and expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: Infants, Children, and Adolescents: IV: 25 to 50 mg/kg/dose IV every 8 to 12 hours. Maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (ARC): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> ARC is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations that results in increased drug elimination. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥200 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Continuous infusion</i>: 150 mg/kg/day as a continuous infusion; maximum daily dose: 12 g/<b>day</b>. May give an initial loading dose of 30 mg/kg (maximum dose: 2,000 mg/dose) before starting the continuous infusion if rapid attainment of therapeutic drug concentrations is desired (eg, sepsis). Dosing is based on a pharmacokinetic modeling study; additional dosages (eg, lower daily doses, every-6-hour dosing) may be appropriate depending on the clinical situation.</p></div>
<div class="block dohp drugH1Div" id="F51083953"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F147091"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9214" href="/d/html/9214.html" rel="external">see "Cefazolin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fowler.1','lexi-content-ref-19489710','lexi-content-ref-24936596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fowler.1','lexi-content-ref-19489710','lexi-content-ref-24936596'])">Ref</a></span>); treat uncomplicated <i>Staphylococcus</i>
<i> aureus</i> bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for susceptible Enterobacteriaceae</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27836382','lexi-content-ref-21427400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27836382','lexi-content-ref-21427400'])">Ref</a></span>). Usual duration is 7 to 14 days; individualize depending on source and extent of infection as well as clinical response. A 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.1','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.1','lexi-content-ref-30535100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antibiotic lock technique (catheter-salvage strategy):</i>
<b>Note:</b> For infections caused by susceptible organisms when the catheter cannot be removed; use in addition to systemic antibiotics. Catheter salvage is <b>not</b> recommended for <i>S. aureus</i>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intracatheter: </b>Prepare lock solution to final concentration of cefazolin 5 to 10 mg/mL (may be combined with heparin). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL), with a dwell time of up to 72 hours depending on frequency of catheter use and solution stability. Withdraw lock solution prior to catheter use; replace with fresh cefazolin lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193593','lexi-content-ref-Girand.1','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193593','lexi-content-ref-Girand.1','lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="142a8701-080d-49cd-9f46-814412cd152f">Endocarditis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (alternative agent for patients with nonsevere, non-IgE-mediated penicillin allergy who cannot take oral therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 1 g as a single dose 30 to 60 minutes before procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. <b>Note:</b> Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17446442','lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17446442','lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for methicillin-susceptible staphylococci (alternative agent for patients with nonsevere, non-IgE-mediated penicillin allergy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Native valve: <b>IV:</b> 2 g every 8 hours for 6 weeks. <b>Note:</b> Duration intended for <b>complicated</b> right-sided infective endocarditis (IE) or left-sided IE. For <b>uncomplicated</b> right-sided IE, 2 weeks of therapy may be adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Prosthetic valve<i>:</i>
<b>IV:</b> 2 g every 8 hours for ≥6 weeks (combine with rifampin for entire duration of therapy and gentamicin for the first 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with low risk for resistant pathogens (eg, local Enterobacteriaceae resistance rate to cefazolin &lt;10% and no recent antibiotic exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cholecystitis, acute:</i>
<b>IV:</b> 1 to 2 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>). <b>Note:</b> The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Other intra-abdominal infections (eg, perforated appendix, appendiceal abscess, diverticulitis) (off-label use): </i>
<b>IV:</b> 1 to 2 g every 8 hours in combination with metronidazole. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1','lexi-content-ref-26080338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1','lexi-content-ref-26080338'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, pathogen-directed therapy for</i>
<i>methicillin-susceptible<i> S. aureus</i></i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours for ≥6 weeks depending on extent of infection, debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention, following open fractures</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g for patients &lt;120 kg or 3 g for patients ≥120 kg every 8 hours; ideally administer within 6 hours of injury. For type I or II fractures (no more than moderate comminution or contamination, no or minimal periosteal stripping, adequate soft tissue coverage), discontinue 24 hours following wound closure. For type III fractures (severe contamination or comminution), use as part of an appropriate combination regimen and continue for 72 hours after injury or up to 24 hours after wound closure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21610369','lexi-content-ref-Schmitt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21610369','lexi-content-ref-Schmitt.1'])">Ref</a></span>). <b>Note:</b> For patients with risk for methicillin-resistant<i> S. aureus (</i>MRSA), potential water exposure, or fecal or clostridial contamination, alternative or additional antibiotics are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schmitt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schmitt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (peritoneal dialysis patients) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> As a component of empiric therapy in patients at low risk for MRSA or as pathogen-directed therapy. Intraperitoneal administration is preferred to IV administration. Duration of therapy is ≥2 to 3 weeks, depending on organism, for patients with adequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burkart.1','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burkart.1','lexi-content-ref-27282851'])">Ref</a></span>). Consider a 25% dose increase in patients with significant residual renal function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent:</i>
<b>Intraperitoneal:</b> 15 to 20 mg/kg added to one exchange of dialysis solution once daily (allow to dwell for ≥6 hours). For patients on continuous ambulatory peritoneal dialysis, add cefazolin to the overnight dwell. <b>Note:</b> Some experts recommend adding cefazolin to each exchange in patients on automated peritoneal dialysis as nighttime intraperitoneal levels of cefazolin may fall below the minimum inhibitory concentration of most organisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous (with every exchange) (dose is per liter of dialysate):</i>
<b>Intraperitoneal:</b> Loading dose: 500 mg/L of dialysate added to first exchange of dialysate; maintenance dose: 125 mg/L of dialysate with each subsequent exchange of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia: </b>
<i>Pathogen-directed therapy for methicillin-susceptible S. aureus: </i>
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1','lexi-content-ref-30190234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1','lexi-content-ref-30190234'])">Ref</a></span>). Minimum duration is generally 5 days for community-acquired pneumonia and 7 days for hospital-acquired or ventilator-associated pneumonia; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577','lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fbe54bc-cf3e-47a1-a583-1a67cb1fbc77">Prostatitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis, acute bacterial: </b>
<i>Pathogen-directed therapy for susceptible organisms:</i>
<b>IV:</b> 1 g every 8 hours; may switch to oral therapy 24 to 48 hours after improvement in fever and clinical symptoms. Total duration of therapy is 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection: </b>
<i>Pathogen-directed therapy for methicillin-susceptible S. aureus:</i>
<b>IV:</b> 2 g every 8 hours. Duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors. <b>Note:</b> In select cases (eg, debridement and retention of prosthesis or one-stage arthroplasty), combine with oral rifampin and give oral suppressive antibiotic therapy following completion of IV treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b95c4e6-731a-4c54-a07f-d029033f2fd8">Septic arthritis, without prosthetic material</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis, without prosthetic material: </b>
<i>Pathogen-directed therapy for methicillin-susceptible S. aureus:</i>
<b>IV:</b> 2 g every 8 hours. Duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1','lexi-content-ref-28366221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1','lexi-content-ref-28366221'])">Ref</a></span>). Some experts recommend 4 weeks of parenteral therapy for patients with concomitant bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Erysipelas or nonpurulent cellulitis in patients without risk for methicillin-resistant S. aureus:</i>
<b>IV:</b> 1 to 2 g every 8 hours. Total duration of therapy ≥5 days (including oral step-down therapy); may extend to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for methicillin-susceptible S. aureus: </i>
<b> IV: </b>1 to 2 g every 8 hours. Total duration of therapy is 5 to 14 days (including oral step-down therapy) depending on severity of infection, need for debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>). <b>Note:</b> For necrotizing infections, antibiotic therapy must be used in conjunction with early and aggressive surgical exploration and debridement of necrotic tissue; continue until further debridement is not necessary and the patient has clinically improved and is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical site incisional infection (trunk or extremity surgery, not involving axilla or perineum):</i>
<b>IV:</b> 1 g every 8 hours; duration is dependent upon severity, need for debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f8fdde6-bbf9-4ed3-99cc-d4e05b77b439">
<i>Streptococcus</i>, maternal prophylaxis for prevention of neonatal disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i> (group B), maternal prophylaxis for prevention of neonatal disease (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g as a single dose at onset of labor or prelabor rupture of membranes, then 1 g every 8 hours until delivery. Reserve for patients with penicillin allergy who are at <b>low</b> risk for anaphylaxis (eg, rash without urticaria and no systemic symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31977795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31977795'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b>
<b>IV:</b> 2 g for patients &lt;120 kg or 3 g for patients ≥120 kg; administer within 60 minutes of surgical incision. Use in combination with metronidazole for procedures requiring anaerobic coverage (eg, colorectal and clean-contaminated head and neck procedures). May repeat dose intraoperatively in 4 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>); maximum dose: 12 g/day (manufacturer's labeling). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799638'])">Ref</a></span>). Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ef5efb8-e08b-4fb7-b074-447bc1e317f5">Toxic shock syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome (off-label use):</b>
<i>Pathogen-directed therapy for group A streptococcus (alternative agent for patients with nonsevere, non–IgE-mediated penicillin allergy) or methicillin-susceptible S. aureus</i>
<i> (off-label use):</i>
<b>IV:</b> 2 g every 8 hours in combination with clindamycin. In the absence of bacteremia, treat for a total of ≥10 days, including oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chu.2019','lexi-content-ref-Stevens.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chu.2019','lexi-content-ref-Stevens.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b>
<i>Pathogen-directed therapy for susceptible organisms</i>: <b>IV:</b> 1 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7675380','lexi-content-ref-9699761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7675380','lexi-content-ref-9699761'])">Ref</a></span>). Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-20175247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-20175247'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991211"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The following dose adjustments are for the usual recommended dosing of 1 to 2 g IV every 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307987','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307987','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>): <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider an initial unadjusted dose appropriate to the severity of the infection before reducing the dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: 1 to 2 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;50 mL/minute: 1 to 2 g every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;10 to &lt;30 mL/minute: 500 mg to 1 g every 12 hours (some experts give 2 g every 12 hours for severe infections in patients with CrCl 10 to &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)).</p>
<p style="text-indent:0em;margin-left:2em;">CrCl ≤10 mL/minute: 500 mg to 1 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25608584','lexi-content-ref-30137377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25608584','lexi-content-ref-30137377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (45% to 60% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9740156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9740156'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Daily dosing: 500 mg to 1 g every 24 hours (when scheduled dose falls on a dialysis day, administer after dialysis).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">Thrice weekly (post dialysis) dosing: 2 g after dialysis 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-10462306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-10462306'])">Ref</a></span>) <b>or</b> 20 mg/kg (maximum dose: 2 g) after dialysis 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12561661','lexi-content-ref-11273877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12561661','lexi-content-ref-11273877'])">Ref</a></span>) <b>or </b>2 g after dialysis if next dialysis is expected in 48 hours <b>or</b> 3 g after dialysis if next dialysis is expected in 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17173215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17173215'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: IV: </b>500 mg every 12 hours or 1 g every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-6613991','lexi-content-ref-4744017','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-6613991','lexi-content-ref-4744017','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1856121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1856121'])">Ref</a></span>)) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>IV:</b> 2 g loading dose followed by either 1 g every 8 hours or 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1856121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1856121'])">Ref</a></span>)) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g loading dose followed by either 1 g every 8 hours or 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988416"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block arsc drugH1Div" id="F58073875"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection has occurred, including <b>
<i>Clostridioides difficile</i>-associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23871314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23871314'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; potentially related to recent or cumulative antibiotic exposure. Cefazolin may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Exposure to cefazolin during the 4-week period prior to positive <i>C. difficile</i> test (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17713303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17713303'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (third-/fourth-generation cephalosporins among the highest risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospitalization or other healthcare setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors, H<sub>2</sub> blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemolytic anemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemolytic anemia</b> has occurred in patients receiving cephalosporins, including cefazolin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34819145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34819145'])">Ref</a></span>). While extremely rare, hemolytic anemia associated with cefazolin has been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moghaddam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moghaddam.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; no clear consensus about the mechanism of cefazolin-induced hemolytic anemia among limited case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34819145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34819145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; occurs within the first few hours to 7 days after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34819145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34819145'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) range from morbilliform <b>skin rash</b> to rare cases of <b>anaphylaxis</b> and <b>anaphylactic shock</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34464750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34464750'])">Ref</a></span>). <b>Urticaria</b> and <b>angioedema</b> have also occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22093010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22093010'])">Ref</a></span>). Delayed hypersensitivity reactions, including severe cutaneous adverse reactions (SCARs) (<b>acute generalized exanthematous pustulosis</b> [AGEP], <b>Stevens-Johnson syndrome</b> [SJS], and <b>toxic epidermal necrolysis</b> [TEN]) and <b>serum sickness-like reaction</b>, have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33077522','lexi-content-ref-27862184','lexi-content-ref-25954556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33077522','lexi-content-ref-27862184','lexi-content-ref-25954556'])">Ref</a></span>). The incidence of cefazolin hypersensitivity in perioperative settings is low (&lt;1%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33838879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33838879'])">Ref</a></span>). Due to the unique R1-side chain, the incidence of cefazolin hypersensitivity is lower than other beta-lactam antibiotics. For this reason, beta-lactam cross-reactivity is rare, and patients may experience “selective hypersensitivity” to cefazolin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28294589','lexi-content-ref-33729459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28294589','lexi-content-ref-33729459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, including maculopapular rash and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Maculopapular reactions: Intermediate; occur 7 to 10 days after initiation. Other reactions (including SCARs): Varied; occur after 7 to 14 days up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between penicillins and cephalosporins and among cephalosporins is mostly related to side chain similarity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29408440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29408440'])">Ref</a></span>). Studies and a practice parameter have shown negligible cross-reactivity between penicillins and cefazolin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25783308','lexi-content-ref-36122788','lexi-content-ref-34669610','lexi-content-ref-29017833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25783308','lexi-content-ref-36122788','lexi-content-ref-34669610','lexi-content-ref-29017833'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F147058"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (including genital pruritus), skin rash</p>
<p style="text-indent:0em;margin-left:2em;">Gastrointestinal: Abdominal cramps, anorexia, diarrhea, epigastric pain, flatulence, heartburn, nausea, oral candidiasis, oral mucosal ulcer, pruritus ani, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis, vulvovaginal candidiasis, vulvovaginal pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, neutropenia, thrombocytopenia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site, injection-site phlebitis, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, confusion, dizziness, drowsiness, drug fever, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Cleminson 2020), Stevens-Johnson syndrome (Saavedra 2012), toxic epidermal necrolysis (Sriganesh 2018), urticaria (Pipet 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (Hansen 2013), <i>Clostridioides difficile</i> colitis (Hansen 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Mause 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Bogas 2021), anaphylaxis (Bogas 2021), angioedema (Pipet 2011), serum sickness-like reaction (Nguyen 2017)</p>
<p style="text-indent:0em;margin-left:2em;">Renal: Acute interstitial nephritis</p></div>
<div class="block coi drugH1Div" id="F147073"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Immediate hypersensitivity (eg, anaphylaxis, serious skin reactions) to cefazolin, other cephalosporin antibiotics, penicillins, other beta-lactams, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F147055"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated INR: May be associated with increased INR, especially in nutritionally deficient patients, prolonged treatment, hepatic or renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p></div>
<div class="block foc drugH1Div" id="F147067"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/50 mL in Dextrose 4% (50 mL); 2 g/100 mL in Dextrose 4% (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 10 g (1 ea); 100 g (1 ea); 300 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 1 g and Dextrose 4% (1 ea); 2 g and Dextrose 3% (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea); 3 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F147051"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323045"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ceFAZolin Sodium-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/50ML 4% (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM/100ML 4% (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (ceFAZolin Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $1.10 - $7.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $7.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $7.20 - $60.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 g (per each): $144.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 g (per each): $420.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.31 - $9.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (ceFAZolin Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $3.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $5.86 - $7.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 g (per each): $10.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (ceFAZolin Sodium-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM 4%(50ML) (per each): $15.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM 3%(50ML) (per each): $17.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866226"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 10 g (1 ea); 100 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612376"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Deep IM injection into a large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 10 to 60 minutes; may be administered IVP over 3 to 5 minutes.</p></div>
<div class="block adm drugH1Div" id="F802619"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">IM: Inject deep IM into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">IV: Inject direct IV over 3 to 5 minutes or may infuse as an intermittent infusion over 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Some penicillins (eg, carbenicillin, ticarcillin and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>
<div class="block sts drugH1Div" id="F147083"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at room temperature and protect from temperatures exceeding 40°C. Reconstituted solutions of cefazolin are light yellow to yellow. Protection from light is recommended for the powder and for the reconstituted solutions. Reconstituted solutions are stable for 24 hours at room temperature and for 7 to 10 days under refrigeration (varies by manufacturer; refer to product-specific labeling). Stability of parenteral admixture in D5W, D5LR, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, D10W, LR, or NS at room temperature (25°C) is 48 hours. Stability of parenteral admixture at refrigeration temperature (4°C) is 14 days.</p>
<p style="text-indent:-2em;margin-left:2em;">DUPLEX: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) prior to activation; do not freeze. Following activation, stable for 24 hours at room temperature and for 7 days under refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">GALAXY: Store at or below -20°C (-4°F). Thawed solution stable for 48 hours at room temperature and for 30 days under refrigeration. Do not refreeze.</p></div>
<div class="block usep drugH1Div" id="F53565901"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of susceptible infections involving the respiratory tract, skin and skin structure, urinary tract, biliary tract, bone and joint, genitals, and septicemia (FDA approved in ages ≥1 month and adults); perioperative prophylaxis (FDA approved in adults); treatment of bacterial endocarditis (FDA approved in adults); has also been used for bacterial endocarditis prophylaxis for dental and upper respiratory procedures; prophylaxis of peritonitis in patients with peritoneal dialysis (PD) catheters undergoing invasive dental procedures, gastrointestinal or genitourinary procedures, touch contamination prophylaxis of PD catheter, and treatment of peritonitis in patients with peritoneal catheters</p></div>
<div class="block mst drugH1Div" id="F147140"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CeFAZolin may be confused with cefoTEtan, cefOXitin, cefprozil, cefTAZidime, cefTRIAXone, cephalexin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298985"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147060"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: CeFAZolin may increase the serum concentration of Fosphenytoin. Specifically, the ratio of free phenytoin to total phenytoin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: CeFAZolin may increase the serum concentration of Phenytoin. Specifically, the ratio of free phenytoin to total phenytoin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: CeFAZolin may enhance the adverse/toxic effect of RifAMPin. Specifically, the risk for bleeding may be increased.  Management: Avoid concomitant use of rifampin with cefazolin when possible. If combined, closely monitor prothrombin time or other coagulation tests and administer vitamin K as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F147076"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F5944549"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefazolin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, cephalosporin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Czeizel 2001; Lamont 2014; Muanda 2017a; Muanda 2017b). Adverse events have not been reported in the fetus following administration of cefazolin prior to cesarean delivery.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of cefazolin may be altered (Allegaert 2009; Elkomy 2014; Philipson 1987). In addition to pregnancy, obesity has been found to influence the pharmacokinetics of cefazolin (Ahmadzia 2015; Duff 2019; Eley 2020; Groff 2017; Kram 2017; Pevzner 2011; Stitely 2013; Young 2015). Higher doses are recommended in obese patients; however, additional studies are needed to determine the ideal dose, especially in pregnant patients with extreme obesity (ACOG 2018; Dallmann 2019; La Rosa 2020).</p>
<p style="text-indent:0em;margin-top:2em;">A targeted antibiotic such as cefazolin is recommended prior to all cesarean deliveries unless the patient is already receiving an appropriate antibiotic. A single dose administered within 60 minutes prior to the delivery is recommended unless drug allergies are present. Dose adjustments of cefazolin may be considered based on maternal weight (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Cefazolin is recommended as an alternative antibiotic for group B streptococcus (GBS) prophylaxis in pregnant patients who are penicillin allergic and at low risk for anaphylaxis. Treatment is intended to prevent early-onset disease in newborns. Prophylaxis is reserved for pregnant patients with a positive GBS vaginal or rectal screening in late gestation; GBS bacteriuria during the current pregnancy; history of birth of an infant with early-onset GBS disease; and unknown GBS culture status with any of the following: birth &lt;37 0/7 weeks gestation, intrapartum fever, prolonged rupture of membranes, known GBS positive in a previous pregnancy, or intrapartum nucleic acid amplification testing positive for GBS (ACOG 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Cefazolin is one of the recommended antibiotics that may be used prior to vaginal delivery in patients at high risk for endocarditis. This includes patients with congenital heart disease, prosthetic valves, previous infective endocarditis, or cardiac transplant. Cefazolin is given 30 to 60 minutes prior to a vaginal delivery; the endocarditis prophylactic dose is the same as nonpregnant patients (ACOG 2018).</p></div>
<div class="block mopp drugH1Div" id="F53565900"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function periodically when used in combination with other nephrotoxic drugs, hepatic function tests, and CBC; prothrombin time in patients at risk; number and type of stools/day for diarrhea. Monitor closely for signs and symptoms of hypersensitivity including anaphylaxis.</p></div>
<div class="block pha drugH1Div" id="F147054"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147072"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely into most body tissues and fluids including gallbladder, liver, kidneys, bone, sputum, bile, pleural, and synovial; CSF penetration is low.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates (GA: 25 to &lt;32 weeks; PNA: Median: 16 days [range: 3 to 91 days]): 0.39 L/kg (range: 0.31 to 0.52 L/kg) (Balevic 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates (GA: 30 to 40 weeks; PNA: 2 to 28 days): 0.212 to 0.373 L/kg (Deguchi 1988).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to 12 years of age: 0.133 ± 0.015 L/kg (Koshida 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.193 ± 0.064 L/kg (Scheld 1981).</p>
<p style="text-indent:-2em;margin-left:4em;">Bone:serum concentration ratio: Median: 0.25 (range: 0.06 to 0.41) (Zeller 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA: 30 to 40 weeks; PNA: 2 to 28 days): 49% (range: 17% to 78%) (Deguchi 1988); protein binding is decreased (with a resulting higher free fraction) with lower albumin concentrations, higher bilirubin concentration, higher total cefazolin concentration, and lower PMA (Smits 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to 12 years: 78% ± 2.5% (range: 75% to 82.3%) (Koshida 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 80% (Marshall 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates (PNA: 2 to 12 days): IV: 4.05 ± 0.72 hours (range: 2.8 to 4.74 hours) (Sakata 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥9 months of age and children ≤10 years of age: IV: 1.7 ± 0.6 hours (Nahata 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 10 to 12 years of age: IV: 1.95 hours (range 1.44 to 2.88 hours) (Schmitz 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: 1.8 hours; IM: ~2 hours (prolonged with renal impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 0.5 to 2 hours; IV: Within 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70% to 80% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F54850785"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC).</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>S. aureus</i> (methicillin-susceptible [MSSA]): Goal: ≥ ~24% to 55% <i>f</i>T &gt; MIC (bacteriostatic) (Turnidge 1998; Zelenitsky 2018); ≥ ~55% to 100% <i>f</i>T &gt; MIC (bacteriocidal) (Vogelman 1988; Zelenitsky 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>E. coli</i>: Goal: ≥60%<i> f</i>T &gt; MIC (bacteriostatic); ≥100% <i>f</i>T &gt; MIC (2-log kill) (Vogelman 1988).</p>
<p style="text-indent:-2em;margin-left:6em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:8em;">Critically ill patients in the ICU: Minimum goal: ≥50%<i> f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Roberts 2015); some experts favor ≥100%<i> f</i>T ≥4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug concentrations in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥9 months of age and children ≤10 years of age: C<sub>max</sub> (peak), single dose: Mean dose: 22.7 mg/kg ± 4 mg/kg: 137 ± 87.9 mg/L (Nahata 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max </sub>(peak), steady state: 1 g every 8 hours: 94 ± 30.33 mg/L (Bhalodi 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally little to no postantibiotic effect (&lt;1 hour) for streptococci and gram-negative bacilli; for <i>S. aureus</i>: ~4 hours (Craig 1993; Craig 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038553"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Kefzol | Totacef | Zepilen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefazolina | Cefazolina argentia | Cefazolina Drawer | Cefazolina Max Vision | Cefazolina northia | Zolcef</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin aptapharma | Cefazolin mip | Cefazolin sandoz | Kefzol | Zolicef</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Cefazolin aft | Cephazolin alphapharm | Cephazolin sodium | Kefzol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cefalin | Cefazol | Zolibac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazoline Mylan | Cefazoline Sandoz | Kefzol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Cefazolin abr | Zepilen</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Maxibiotic</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cefazolina sodica | Ceftrat | Cellozina | Cezolin | Fazolon | Kefalin | Kefazol | Zolidina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin labatec | Kefzol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefamezin sodium | Cefazolin | Cefrazolin sodium | Na lin | Sai fu ning | Xin tai lin | Zhuo zheng</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazolina | Cefazolina sodica | Fazopira | Kefzol | Zolibios</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Azepo | Cefazolin | Cefazoline | Kefzol | Orizolin | Vulmizolin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Baktozil | Basocef | Cefazolin | Cefazolin Eberth | Cefazolin normon | Cefazolin qilu | Cefazolin saar | Cefodinin | Cephazolin | Saarzolin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alcovera | Cefazolina | Intrazolina | Kefzol | Prisolin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazolina | Kefzol | Zolidina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Cefazolin nycomed | Cezolin | Kefzol | Totacef | Zepilen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Kefzol | Totacef | Zinol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Areuzolin | Brizolina | Cefamezin | Cefaresan | Cefazolina cepa | Cefazolina G.E.S. | Cefazolina ldp-laboratorios torlan | Cefazolina llorente | Cefazolina normon | Cefazolina Reig Jofre | Fazoplex | Intrazolina | Kefol | Tasep | Tecfazolina | Zepilen | Zolival</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Kefzol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazoline Flavelab | Cefazoline merck | Cefazoline panpharma | Kefzol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kefzol | Trav cephazolin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kefzol | Vifazolin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Stazolin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin BCPP | Zepilen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin aptapharma | Cefazolin human | Cefazolin mip | Cefazolin panpharma | Kefzol | Totacef</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Biozolin | Cefamezin | Cefazol | Cefazolin | Evalin | Venozol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Kefazin | Totacef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alcizon | Azolin | Cefazolin | Cezolin | Nostof | Orizolin | Prezolin | Prilex | Reflin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cefabiozim | Cefamezin | Cefazil | Cefazina | Cefazolina | Cefazolina acs | Cefazolina drm | Cefazolina k24 | Cefazolina union health | Cromezin | Nefazol | Recef | Silzolin | Totacef</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin sandoz | Hikma cefazolin | Zolecef</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefamezin alpha | Cefamezol | Cefazopen | Cenazine | Efunikol | Rasenazolin hexal | Rasenazolin maruko | Sefmazon | Synclomedin | Taicezolin sanken | Taicezolin taiyo | Taicezolin towa | Tokio</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cefzole | Cezol | Fazlin | Fezolin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefanzol | Cefarizon | Cefazolin | Cefazoline yungjin | Cefozol | Ckd cefazolin | Hanlim cefazoline sodium | Kepodon | Kukje cefazoline | Union cefazoline | Yoo young cefazolin sodium | Yuhan cefazoline</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin sandoz | Zolecin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cefazoline</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Cefazolin mip | Cezolin | Intrazoline | Kefzol | Lysolin | Orizolin | Pan-cefazolin | Reflin | Rezol | Totacef | Vulmizolin | Zepilen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cephazolin | Kefzol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Cefazolin BCPP | Cefazolin mip | Cezolin | Kefzol | Lysolin | Orizolin | Pan-cefazolin | Reflin | Totacef | Vulmizolin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kefzol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Cefazolin aft</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazoline Aurobindo | Cefazoline Hospira | Cefazoline Mylan | Cefazoline Sandoz | Kefzol | Servazolin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Cefazolin hexal | Cefazolin Reig Jofre</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Cephazolin | Cephazolin sodium | Kefzol | M cefazolin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cecan | Cefacidal | Cefazaliph | Cefazolina | Cephlin | Kefzol | Primacef | Proxicaf | Reflin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">2 World Cefazolin | Cefalin | Cefavex | Cefazol | Cefazole | Cefazovit | Cifoxim | Cizo | Cloviz | Faxilen | Fazef | Fazol | Fazolin | Fazonil | Fonvicol | Hazolin | Ilozef | Lozan | May cefazolin | Megacef | Novazef | Phizolin | Samarial | Sanzol | Solosprin | Stancef | Zofacef | Zolival</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Afazole | Amrozolin | Avezol | Biozolin | C-zol | Cefamezin | Cefasol | Cefazol | Cefazolin | Cefzo | Celex | Cezolin | Curolin | Kavelin | Kefone | Kefzol | Kefzomed | Medizol | Nelzim | Parmazolin | Pefzol | Sazolene | Zolocef</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biofazolin | Cefamezin | Cefazolin | Cefazolin mip | Cefazolin tzf | Kefzol | Tarfazolin | Vulmizolin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ancef | Cefazolin | Kefzol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cefazolina hikma | Cefazolina normon | Cefazolina pharmis | Cefazolina sandoz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cefazoland | Cefazolina genfar | Cefazolina hospicenter | Cefazolina interlabo | Cefazolina millet | Cefazolina northia | Cefazolina richet | Lexibac evim | Mediforina | Novo cefacilin | Novo talexin | Novo thidoxol | Zolidina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefamezin IM | Hikma Cefazolin | Zepilen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kefzol | Zolinef</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ancef | Cefamezin | Cefaxon | Cefazolin | Cefazolin akos | Cefazolin Elfa | Cefazolin sandoz | Cefazolin vatchem | Cefezol | Cefoprid | Cezolin | Intrazoline | Kefotex | Kefzol | Lizolin | Lysolin | Lyzolin | Nacef | Orizolin | Orpin | Prozolin | Reflin | Totacef | Zolfin | Zolin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Kefzol | Tazoline | Totacef | Zepilen | Zolecin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin mip | Celmetin | Kefzol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin | Cefazoline | Cezolin | Zepilen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Altazolin | Cefamezin | Cefazolin actavis | Cefazolin Apta | Kefzol | Zepilen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazolin | Kefzol | Vulmizolin | Zepilen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anbizolin | Cefaben | Cefacidal im/iv | Cefalin | Cefamezin | Cefazillin | Cefazol | Cefazolin | Cefazolin meiji | Cefolin | Cefono | Cefzolin | Fazolin | Pharlin | Zefa m h | Zepilen | Zofalin | Zolicef | Zolimed</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cefamezin | Cefazol | Cefazolin | Cefazoline | Zepilen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Befazol | Cefamezin | Cefozin | Cezol | Eqizolin | Iespor | Maksiporin | Maxicilin | Sefamax | Sefazol | Vansef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cefa | Cefacin | Cefamezin | Cefazin | Cefazo | Cefazolin | Cepha | Cephazolin | Cezolin | Kefzol | Kelin | Kofatol | Leadercef | Lofalin | Lyo Sefa | Meisin | Oricef | Sezolin | Stazolin | Uzolin | Veterin | Winzolin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cefazex | Cefazolin | Cefazolin combi | Cefazolinum | Cezolin | Ifizol | Kefzol | Nacef | Reflin | Totacef | Zolfin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Zepilen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cefazolina | Cefazolina northia | Zolidina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazolina | Cellozina | Efaztas | Kefzol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Cefazolin acs dobfar | Erabru | Philfazolin | Shinzolin | Yuhan Cefazolin | Zolifast</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cefacidal | Cefazolin oethmaan | Cefazolin-fresenius | Kefzol | Mylan Cefazolin | Pharmacare cefazolin | Ranzol | Sabax cefazolin | Zefkol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Kefzol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12561661">
<a name="12561661"></a>Ahern JW, Possidente CJ, Hood V, Alston WK. Cefazolin dosing protocol for patients receiving long-term hemodialysis. <i>Am J Health Syst Pharm.</i> 2003;60(2):178-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/12561661/pubmed" id="12561661" target="_blank">12561661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26348186">
<a name="26348186"></a>Ahmadzia HK, Patel EM, Joshi D, et al. Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women. <i>Obstet</i>
<i>Gynecol</i>. 2015;126(4):708-715. doi:10.1097/AOG.0000000000001064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26348186/pubmed" id="26348186" target="_blank">26348186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; and The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19006783">
<a name="19006783"></a>Allegaert K, van Mieghem T, Verbesselt R, et al, "Cefazolin Pharmacokinetics in Maternal Plasma and Amniotic Fluid During Pregnancy," <i>Am J Obstet Gynecol</i>, 2009, 200(2):170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19006783/pubmed" id="19006783" target="_blank">19006783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28294589">
<a name="28294589"></a>Almeida JP, Lopes A, Campos Melo A, Pereira Santos MC, Pereira Barbosa M. Selective hypersensitivity to cefazolin and contribution of the basophil activation test. <i>Eur Ann Allergy Clin Immunol</i>. 2017;49(2):84-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28294589/pubmed" id="28294589" target="_blank">28294589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett E, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018;132(3):e103-e119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31977795">
<a name="31977795"></a>American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion, number 797. <i>Obstet Gynecol</i>. 2020;135(2):e51-e72. doi:10.1097/AOG.0000000000003668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/31977795/pubmed" id="31977795" target="_blank">31977795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs, “Combating Antibiotic Resistance,” <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799638">
<a name="24799638"></a>Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control</i>
<i>Hosp </i>
<i>Epidemiol. </i>2014;35(6):605-627. doi: 10.1086/676022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24799638/pubmed" id="24799638" target="_blank">24799638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30944398">
<a name="30944398"></a>Balevic SJ, Smith PB, Testoni D, et al. Cefazolin pharmacokinetics in premature infants. <i>J Perinatol.</i> 2019;39(9):1213-1218. doi:10.1038/s41372-019-0368-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30944398/pubmed" id="30944398" target="_blank">30944398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31307987">
<a name="31307987"></a>Bellouard R, Deschanvres C, Deslandes G, et al. Population pharmacokinetic study of cefazolin dosage adaptation in bacteremia and infective endocarditis based on a nomogram. <i>Antimicrob Agents Chemother</i>. 2019;63(10):e00806-19. doi:10.1128/AAC.00806-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/31307987/pubmed" id="31307987" target="_blank">31307987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25783308">
<a name="25783308"></a>Beltran RJ, Kako H, Chovanec T, Ramesh A, Bissonnette B, Tobias JD. Penicillin allergy and surgical prophylaxis: cephalosporin cross-reactivity risk in a pediatric tertiary care center. <i>J Pediatr Surg</i>. 2015;50(5):856-859. doi:10.1016/j.jpedsurg.2014.10.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25783308/pubmed" id="25783308" target="_blank">25783308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi:10.1093/cid/civ482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017 [published correction appears in <i>JAMA Surg. </i>2017;152(8):803]. <i>JAMA Surg</i>. 2017;152(8):784-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24041887">
<a name="24041887"></a>Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. <i>Antimicrob Agents Chemother.</i> 2013;57(11):5679-5683. doi:10.1128/AAC.01348-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24041887/pubmed" id="24041887" target="_blank">24041887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35203881">
<a name="35203881"></a>Bianchini S, Rigotti E, Monaco S, et al. Surgical antimicrobial prophylaxis in abdominal surgery for neonates and paediatrics: a RAND/UCLA appropriateness method consensus study. <i>Antibiotics (Basel)</i>. 2022;11(2):279. doi:10.3390/antibiotics11020279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/35203881/pubmed" id="35203881" target="_blank">35203881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34464750">
<a name="34464750"></a>Bogas G, Doña I, Dionicio J, et al. Diagnostic approach of hypersensitivity reactions to cefazolin in a large prospective cohort. <i>J Allergy Clin Immunol Pract</i>. 2021;9(12):4421-4430.e4. doi:10.1016/j.jaip.2021.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/34464750/pubmed" id="34464750" target="_blank">34464750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193593">
<a name="19193593"></a>Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. <i>Ann Pharmacother. </i>2009;43(2):210-219. doi: 10.1345/aph.1L145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19193593/pubmed" id="19193593" target="_blank">19193593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022: 97-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6613991">
<a name="6613991"></a>Bunke CM, Aronoff GR, Luft FC. Pharmacokinetics of common antibiotics used in continuous ambulatory peritoneal dialysis. <i>Am J Kidney Dis</i>. 1983;3(2):114-117. doi:10.1016/s0272-6386(83)80025-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/6613991/pubmed" id="6613991" target="_blank">6613991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burkart.1">
<a name="Burkart.1"></a>Burkart JM. Microbiology and therapy of peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefazolin.1">
<a name="Cefazolin.1"></a>Cefazolin for Injection Pharmacy Bulk Package [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefazolin.2">
<a name="Cefazolin.2"></a>Cefazolin for Injection 500 mg and 1 g vials [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefazolin.3">
<a name="Cefazolin.3"></a>Cefazolin in dextrose Duplex container [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Cefazolin injection 2 and 3 g vials [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefazolin.4">
<a name="Cefazolin.4"></a>Cefazolin Sodium in Dextrose injection Galaxy container [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefazolin.5">
<a name="Cefazolin.5"></a>Cefazolin 1 and 2 g vials [prescribing information]. Weston, FL: Apotex Corp; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff</i>. 2023. Available at <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chu.2019">
<a name="Chu.2019"></a>Chu VH. Staphylococcal toxic shock syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33077522">
<a name="33077522"></a>Cleminson K, Cunningham N. Acute generalized exanthematous pustulosis. <i>CMAJ</i>. 2020;192(42):E1268. doi:10.1503/cmaj.200324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/33077522/pubmed" id="33077522" target="_blank">33077522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis</i>. 1998;26(1):1-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8335516">
<a name="8335516"></a>Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. <i>J Antimicrob Chemother.</i> 1993;31(suppl D):149-158. doi:10.1093/jac/31.suppl_d.149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/8335516/pubmed" id="8335516" target="_blank">8335516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11349204">
<a name="11349204"></a>Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. <i>Am J Obstet Gynecol</i>. 2001;184(6):1289-1296. doi:10.1067/mob.2001.113905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/11349204/pubmed" id="11349204" target="_blank">11349204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30894099">
<a name="30894099"></a>Dallmann A, Mian P, Van den Anker J, Allegaert K. Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. <i>Curr</i>
<i>Pharm</i>
<i>Des</i>. 2019;25(5):483-495. doi:10.2174/1381612825666190320135137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30894099/pubmed" id="30894099" target="_blank">30894099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492261">
<a name="24492261"></a>De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. <i>J Antimicrob Chemother</i>. 2014;69(5):1330-1338. doi:10.1093/jac/dkt527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24492261/pubmed" id="24492261" target="_blank">24492261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3210156">
<a name="3210156"></a>Deguchi Y, Koshida R, Nakashima E, et al. Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. <i>J Pharm Sci</i>. 1988;77(8):674-678. doi:10.1002/jps.2600770807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3210156/pubmed" id="3210156" target="_blank">3210156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22479065">
<a name="22479065"></a>Donnelly RF. Stability of cefazolin sodium in polypropylene syringes and polyvinylchloride minibags. <i>Can J Hosp Pharm</i>. 2011;64(4):241-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22479065/pubmed" id="22479065" target="_blank">22479065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21859939">
<a name="21859939"></a>Douglas A, Udy AA, Wallis SC, et al. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. <i>Antimicrob Agents Chemother.</i> 2011;55(11):5238-5242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21859939/pubmed" id="21859939" target="_blank">21859939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107253">
<a name="31107253"></a>Duff P. Prevention of infection after cesarean delivery. <i>Clin Obstet Gynecol</i>. 2019;62(4):758-770. doi:10.1097/GRF.0000000000000460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/31107253/pubmed" id="31107253" target="_blank">31107253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16368422">
<a name="16368422"></a>Edwards FH, Engelman RM, Houck P, et al, “The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration,” <i>Ann Thorac Surg</i>, 2006, 81(1):397-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/16368422/pubmed" id="16368422" target="_blank">16368422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32250982">
<a name="32250982"></a>Eley VA, Christensen R, Ryan R, et al. Prophylactic cefazolin dosing in women with body mass index &gt;35 kg·m-2 undergoing cesarean delivery: a pharmacokinetic study of plasma and interstitial fluid. <i>Anesth Analg</i>. 2020;131(1):199-207. doi:10.1213/ANE.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/32250982/pubmed" id="32250982" target="_blank">32250982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733461">
<a name="24733461"></a>Elkomy MH, Sultan P, Drover DR, Epshtein E, Galinkin JL, Carvalho B. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. <i>Antimicrob Agents Chemother</i>. 2014;58(6):3504-3513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24733461/pubmed" id="24733461" target="_blank">24733461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17383396">
<a name="17383396"></a>Engelman R, Shahian D, Shemin R, et al, “The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice,” <i>Ann Thorac Surg</i>, 2007, 83(4):1569-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17383396/pubmed" id="17383396" target="_blank">17383396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33838879">
<a name="33838879"></a>Fosnot S, Currier K, Pendell J, Jeffres MN. Comparison of immediate hypersensitivity reactions to preoperative antibiotics in patients labeled as penicillin allergic. <i>Surgery</i>. 2021;170(3):777-782. doi:10.1016/j.surg.2021.02.063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/33838879/pubmed" id="33838879" target="_blank">33838879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fowler.1">
<a name="Fowler.1"></a>Fowler VG, Holland TL. Clinical approach to Staphylococcus aureus bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Girand.1">
<a name="Girand.1"></a>Girand HL, McNeil JC. Lock therapy for intravascular non-hemodialysis catheter-related infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.1">
<a name="Goldenberg.1"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28638306">
<a name="28638306"></a>Groff SM, Fallatah W, Yang S, et al. Effect of maternal obesity on maternal-fetal transfer of preoperative cefazolin at cesarean section.<i> J Pediatr</i>
<i>Pharmacol</i>
<i>Ther</i>. 2017;22(3):227-232. doi:10.5863/1551-6776-22.3.227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28638306/pubmed" id="28638306" target="_blank">28638306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care</i>. 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis.</i> 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23871314">
<a name="23871314"></a>Hansen D, Pollan LD, Fernando H. Fulminant <i>Clostridium difficile</i> colitis: a complication of perioperative antibiotic prophylaxis. <i>J Oral Maxillofac Surg</i>. 2013;71(11):1880-1885. doi:10.1016/j.joms.2013.04.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23871314/pubmed" id="23871314" target="_blank">23871314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7351609">
<a name="7351609"></a>Hiner LB, Baluarte HJ, Polinsky MS, Gruskin AB. Cefazolin in children with renal insufficiency. <i>J Pediatr</i>. 1980;96(2):335-339. doi:10.1016/s0022-3476(80)80842-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/7351609/pubmed" id="7351609" target="_blank">7351609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22316145">
<a name="22316145"></a>Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin Dosing for Surgical Prophylaxis in Morbidly Obese Patients. <i>Surg Infect</i>. 2012;13(1):33-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22316145/pubmed" id="22316145" target="_blank">22316145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21610369">
<a name="21610369"></a>Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. <i>J Trauma. </i>2011;70(3):751-754. doi: 10.1097/TA.0b013e31820930e5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21610369/pubmed" id="21610369" target="_blank">21610369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20175247">
<a name="20175247"></a>Hooton TM, Bradley SF, Cardenas DD, et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(5):625-663. doi: 10.1086/650482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/20175247/pubmed" id="20175247" target="_blank">20175247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27836382">
<a name="27836382"></a>Hsieh CC, Lee CH, Hong MY, et al. Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset <i>Escherichia coli</i>, <i>Klebsiella</i> spp. and <i>Proteus mirabilis</i> bacteraemia. <i>Int J Antimicrob Agents</i>. 2016;48(6):712-718. doi: 10.1016/j.ijantimicag.2016.09.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27836382/pubmed" id="27836382" target="_blank">27836382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23457071">
<a name="23457071"></a>Jevsevar DS and Abt E, "The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures," <i>J Am Acad Orthop Surg</i>, 2013, 21(3):195-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23457071/pubmed" id="23457071" target="_blank">23457071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published corrections appear in <i>Clin Infect Dis</i>. 2017;64(9):1298; <i>Clin Infect Dis.</i> 2017;65(8):1435; <i>Clin Infect Dis.</i> 2017;65(12):2161]. <i>Clin Infect Dis.</i> 2016;63(5):e61-e111. doi: 10.1093/cid/ciw353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36122788">
<a name="36122788"></a>Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. <i>J Allergy Clin Immunol</i>. 2022;150(6):1333-1393. doi:10.1016/j.jaci.2022.08.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/36122788/pubmed" id="36122788" target="_blank">36122788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3437384">
<a name="3437384"></a>Koshida R, Nakashima E, Ichimura F, et al. Comparative distribution kinetics of cefazolin and tobramycin in children.<i> J Pharmacobiodyn.</i> 1987;10(9):436-442. doi:10.1248/bpb1978.10.436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3437384/pubmed" id="3437384" target="_blank">3437384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28122314">
<a name="28122314"></a>Kram JJF, Greer DM, Cabrera O, Burlage R, Forgie MM, Siddiqui DS. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? <i>Eur J Obstet Gynecol Reprod Biol</i>. 2017;210:334-341. doi:10.1016/j.ejogrb.2017.01.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28122314/pubmed" id="28122314" target="_blank">28122314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10462306">
<a name="10462306"></a>Kuypers D, Vanwalleghem J, Maes B, Messiaen T, Vanrenterghem Y, Peetermans WE. Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. <i>Nephrol Dial Transplant</i>. 1999;14(8):2050-2051. doi:10.1093/ndt/14.8.2050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10462306/pubmed" id="10462306" target="_blank">10462306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31811413">
<a name="31811413"></a>La Rosa M, Omere C, Redfern T, et al. The impact of low-dose versus high-dose antibiotic prophylaxis regimens on surgical site infection rates after cesarean delivery. <i>Arch Gynecol Obstet</i>. 2020;301(1):69-73. doi:10.1007/s00404-019-05370-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/31811413/pubmed" id="31811413" target="_blank">31811413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4744017">
<a name="4744017"></a>Levison ME, Levison SP, Ries K, Kaye D. Pharmacology of cefazolin in patients with normal and abnormal renal function. <i>J Infect Dis</i>. 1973;128(suppl):S354-S357. doi:10.1093/infdis/128.supplement_2.s354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/4744017/pubmed" id="4744017" target="_blank">4744017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24936596">
<a name="24936596"></a>Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. <i>Antimicrob Agents Chemother.</i> 2014;58(9):5117-5124. doi:10.1128/AAC.02800-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24936596/pubmed" id="24936596" target="_blank">24936596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment [published correction appears in <i>Perit Dial Int</i>. 2018;38(4):313]. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi: 10.3747/pdi.2016.00078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, International Society for Peritoneal Dialysis (ISPD), et al. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int.</i> 2010;30(4):393-423. doi: 10.3747/pdi.2010.00049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2018;38(4):309-310. doi: 10.3747/pdi.2018.00026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17713303">
<a name="17713303"></a>Manian FA, Aradhyula S, Greisnauer S, Senkel D, Setzer J, Wiechens M, Meyer PL. Is it <i>Clostridium difficile</i> infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea. <i>South Med J</i>. 2007;100(8):782-786. doi:10.1097/SMJ.0b013e318063e9c5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17713303/pubmed" id="17713303" target="_blank">17713303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF and Blair JE, “The Cephalosporins,” <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9740156">
<a name="9740156"></a>Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. <i>Am J Kidney Dis</i>. 1998;32(3):410-414. doi:10.1053/ajkd.1998.v32.pm9740156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/9740156/pubmed" id="9740156" target="_blank">9740156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34819145">
<a name="34819145"></a>Mause E, Selim M, Velagapudi M. Cefazolin-induced hemolytic anemia: a case report and systematic review of literature. <i>Eur J Med Res</i>. 2021;26(1):133. doi:10.1186/s40001-021-00604-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/34819145/pubmed" id="34819145" target="_blank">34819145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis</i>. 2010;50(7):1079; <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.1">
<a name="Meyrier.1"></a>Meyrier A, Fekete T. Acute bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7675380">
<a name="7675380"></a>Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. <i>Obstet Gynecol.</i> 1995;86(4, pt 1):560-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/7675380/pubmed" id="7675380" target="_blank">7675380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30190234">
<a name="30190234"></a>Miller MA, Fish DN, Barber GR, et al. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections [published online ahead of print August 18, 2018]. <i>J Microbiol Immunol Infect</i>. doi:10.1016/j.jmii.2018.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30190234/pubmed" id="30190234" target="_blank">30190234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.1">
<a name="Moehring.1"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 2, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moghaddam.1">
<a name="Moghaddam.1"></a>Moghaddam M, Razzaghi F, Sheibani H, Pourfathollah AA. A fatal case of cefazolin-induced immune hemolytic anemia in Iran. <i>J Clin Exp Pathol. </i>2016. doi:10.4172/2161-0681.1000296</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25038006">
<a name="25038006"></a>Murray MT, Corda R, Turcotte R, Bacha E, Saiman L, Krishnamurthy G. Implementing a standardized perioperative antibiotic prophylaxis protocol for neonates undergoing cardiac surgery. <i>Ann Thorac Surg</i>. 2014;98(3):927-933. doi:10.1016/j.athoracsur.2014.04.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25038006/pubmed" id="25038006" target="_blank">25038006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1936061">
<a name="1936061"></a>Nahata MC, Durrell DE, Ginn-Pease ME, King DR. Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. <i>Eur J Drug Metab Pharmacokinet.</i> 1991;16(1):49-52. doi:10.1007/BF03189874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/1936061/pubmed" id="1936061" target="_blank">1936061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]<i>. </i> 2014. Available at https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27862184">
<a name="27862184"></a>Nguyen CV, Miller DD. Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. <i>J Cutan Pathol</i>. 2017;44(2):177-182. doi:10.1111/cup.12863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27862184/pubmed" id="27862184" target="_blank">27862184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Aaron JT. Osteomyelitis in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422859">
<a name="21422859"></a>Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. <i>Obstet Gynecol</i>. 2011;117(4):877-882.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21422859/pubmed" id="21422859" target="_blank">21422859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3829560">
<a name="3829560"></a>Philipson A, Stiernstedt G, and Ehrnebo M, "Comparison of the Pharmacokinetics of Cephradine and Cefazolin in Pregnant and Non-Pregnant Women," <i>Clin Pharmacokinet</i>, 1987, 12(2):136-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3829560/pubmed" id="3829560" target="_blank">3829560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22093010">
<a name="22093010"></a>Pipet A, Veyrac G, Wessel F, Jolliet P, Magnan A, Demoly P, Bousquet PJ. A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities. <i>Clin Exp Allergy</i>. 2011;41(11):1602-1608. doi:10.1111/j.1365-2222.2011.03846.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22093010/pubmed" id="22093010" target="_blank">22093010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25608584">
<a name="25608584"></a>Roberts JA, Udy AA, Jarrett P, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>J Antimicrob Chemother.</i> 2015;70(5):1495-1502. doi:10.1093/jac/dku564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25608584/pubmed" id="25608584" target="_blank">25608584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428165">
<a name="3428165"></a>Robinson DC, Cookson TL, and Grisafe JA, “Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,” <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3428165/pubmed" id="3428165" target="_blank">3428165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408440">
<a name="29408440"></a>Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol Pract</i>. 2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29408440/pubmed" id="29408440" target="_blank">29408440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28366221">
<a name="28366221"></a>Ross JJ. Septic arthritis of native joints. <i>Infect Dis Clin North Am.</i> 2017;31(2):203-218. doi: 10.1016/j.idc.2017.01.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28366221/pubmed" id="28366221" target="_blank">28366221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25954556">
<a name="25954556"></a>Saavedra C, Cárdenas P, Castellanos H, Contreras K, Castro JR. Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine. <i>Case Reports Immunol</i>. 2012;2012:931528. doi:10.1155/2012/931528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25954556/pubmed" id="25954556" target="_blank">25954556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6946258">
<a name="6946258"></a>Sakata Y. The pharmacokinetic studies of cephalothin, cefazolin and cefmetazole in the neonates and the premature babies. <i>Kurume Med J</i>. 1980;27(4):275-298. doi:10.2739/kurumemedj.27.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/6946258/pubmed" id="6946258" target="_blank">6946258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26080338">
<a name="26080338"></a>Salminen P, Paajanen H, Rautio T, et al. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: The APPAC randomized clinical trial. <i>JAMA</i>. 2015;313(23):2340-2348. doi: 10.1001/jama.2015.6154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26080338/pubmed" id="26080338" target="_blank">26080338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32360445">
<a name="32360445"></a>Salvador E, Oualha M, Bille E, et al. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. <i>Clin Microbiol Infect</i>. 2021;27(3):413-419. doi:10.1016/j.cmi.2020.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/32360445/pubmed" id="32360445" target="_blank">32360445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34669610">
<a name="34669610"></a>Sarfani S, Stone CA Jr, Murphy GA, Richardson DR. Understanding penicillin allergy, cross-reactivity, and antibiotic selection in the preoperative setting.<i> J Am Acad Orthop Surg</i>. 2022;30(1):e1-e5. doi:10.5435/JAAOS-D-21-00422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/34669610/pubmed" id="34669610" target="_blank">34669610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6454387">
<a name="6454387"></a>Scheld WM, Spyker DA, Donowitz GR, Bolton WK, Sande MA. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. <i>Antimicrob Agents Chemother.</i> 1981;19(4):613-619. doi:10.1128/aac.19.4.613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/6454387/pubmed" id="6454387" target="_blank">6454387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1856121">
<a name="1856121"></a>Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. <i>J Antimicrob Chemother</i>. 1991;27(4):405-425. doi:10.1093/jac/27.4.405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/1856121/pubmed" id="1856121" target="_blank">1856121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schmitt.1">
<a name="Schmitt.1"></a>Schmitt SK. Osteomyelitis associated with open fractures in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25941220">
<a name="25941220"></a>Schmitz ML, Blumer JL, Cetnarowski W, Rubino CM. Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years. <i>Antimicrob Agents Chemother.</i> 2015;59(7):4173-4180. doi:10.1128/AAC.00082-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/25941220/pubmed" id="25941220" target="_blank">25941220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22833246">
<a name="22833246"></a>Smits A, Kulo A, Verbesselt R, et al. Cefazolin plasma protein binding and its covariates in neonates. <i>Eur J Clin Microbiol Infect Dis</i>. 2012;31(12):3359-3365. doi:10.1007/s10096-012-1703-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22833246/pubmed" id="22833246" target="_blank">22833246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;15;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33729459">
<a name="33729459"></a>Sousa-Pinto B, Blumenthal KG, Courtney L, Mancini CM, Jeffres MN. Assessment of the Frequency of dual allergy to penicillins and cefazolin: a systematic review and meta-analysis. <i>JAMA Surg</i>. 2021;156(4):e210021. doi:10.1001/jamasurg.2021.0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/33729459/pubmed" id="33729459" target="_blank">33729459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11273877">
<a name="11273877"></a>Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. <i>Am J Kidney Dis.</i> 2001;37(4):766-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/11273877/pubmed" id="11273877" target="_blank">11273877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368912">
<a name="28368912"></a>Sriganesh K, Das BP, Rao KVLN. Toxic epidermal necrolysis in a neurosurgical patient. <i>J Neurosurg Anesthesiol</i>. 2018;30(4):374-376. doi:10.1097/ANA.0000000000000429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/28368912/pubmed" id="28368912" target="_blank">28368912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.2019">
<a name="Stevens.2019"></a>Stevens DL. Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23859672">
<a name="23859672"></a>Stitely M, Sweet M, Slain D, Alons L, Holls W, Hochberg C, Briggs F. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug. <i>Surg Infect (Larchmt)</i>. 2013;14(5):455-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/23859672/pubmed" id="23859672" target="_blank">23859672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17173215">
<a name="17173215"></a>Stryjewski ME, Szchech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia. <i>Clin Inf Dis. </i>2007;44(2):191-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17173215/pubmed" id="17173215" target="_blank">17173215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. <i>Perit Dial Int.</i> 2018;38(4):311-312. doi: 10.3747/pdi.2018.00046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21427400">
<a name="21427400"></a>Turnidge JD; Subcommittee on Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints. <i>Clin Infect Dis.</i> 2011;52(7):917-924. doi: 10.1093/cid/cir031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/21427400/pubmed" id="21427400" target="_blank">21427400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis.</i> 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65. doi:10.2165/00148581-200406010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3139779">
<a name="3139779"></a>Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. <i>J Infect Dis.</i> 1988;158(4):831-847. doi:10.1093/infdis/158.4.831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/3139779/pubmed" id="3139779" target="_blank">3139779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. <i>Circulation.</i> 2007;116(15):1736-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9699761">
<a name="9699761"></a>Wing DA, Hendershott CM, Debuque L, Millar LK. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. <i>Obstet Gynecol.</i> 1998;92(2):249-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/9699761/pubmed" id="9699761" target="_blank">9699761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30137377">
<a name="30137377"></a>Wong G, Briscoe S, McWhinney B, et al. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. <i>J Antimicrob Chemother</i>. 2018;73(11):3087-3094. doi:10.1093/jac/dky314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30137377/pubmed" id="30137377" target="_blank">30137377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial [published online ahead of print December 11, 2018]. <i>Clin Infect Dis.</i> doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-758399">
<a name="758399"></a>Yoshioka H, Cho K, Takimoto M, et al. Transfer of Cefazolin Into Human Milk. <i>J Pediatr</i>. 1979;94(1):151-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/758399/pubmed" id="758399" target="_blank">758399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26103528">
<a name="26103528"></a>Young OM, Shaik IH, Twedt R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. <i>Am J Obstet Gynecol</i>. 2015;213(4):541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/26103528/pubmed" id="26103528" target="_blank">26103528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29017833">
<a name="29017833"></a>Zagursky RJ, Pichichero ME. Cross-reactivity in β-lactam allergy. <i>J Allergy Clin Immunol Pract</i>. 2018;6(1):72-81.e1. doi:10.1016/j.jaip.2017.08.027. Epub 2017 Oct 7. Erratum in: <i>J Allergy Clin Immunol Pract</i>. 2022;10(2):651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29017833/pubmed" id="29017833" target="_blank">29017833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29635472">
<a name="29635472"></a>Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. <i>J Antimicrob Chemother</i>. 2018;73(7):1888-1894. doi:10.1093/jac/dky120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/29635472/pubmed" id="29635472" target="_blank">29635472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19075069">
<a name="19075069"></a>Zeller V, Durand F, Kitzis MD, et al. Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations. <i>Antimicrob Agents Chemother.</i> 2009;53(3):883-887. doi:10.1128/AAC.00389-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefazolin-pediatric-drug-information/abstract-text/19075069/pubmed" id="19075069" target="_blank">19075069</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13124 Version 409.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
